



May 17, 2011

Vertex Appoints Terrence C. Kearney to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Vertex Pharmaceuticals Incorporated](#) (Nasdaq: VRTX) today announced that Terrence C. Kearney has joined its board of directors. The addition of Mr. Kearney brings the number of Vertex board members to nine. Mr. Kearney was appointed to the class of directors whose term expires in 2013.

"Mr. Kearney's more than 30 years of financial leadership experience in the life science industry will be invaluable to our Board as Vertex advances toward becoming a cash flow and earnings positive company in 2012," said Matthew Emmens, Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. "I look forward to Terry's insights and welcome him to our Board."

Mr. Kearney has more than three decades of global health care experience at major pharmaceutical and life sciences companies. Most recently, Mr. Kearney served on the executive management team for Hospira, Inc., where he held the role of Chief Operating Officer from 2006 through 2010 and Chief Financial Officer from 2004 to 2006. In these roles, Mr. Kearney had broad responsibility for the company's global operations, including commercial, manufacturing and research and development activities, and financial management strategies. Prior to Hospira, Mr. Kearney spent more than 20 years at Abbott Laboratories in various financial management roles, including Vice President and Treasurer. Mr. Kearney earned a bachelor's degree in biology from the University of Illinois and a master's in business administration from the University of Denver.

About Vertex

Vertex creates new possibilities in medicine. Our team aims to discover, develop and commercialize innovative therapies so people with serious diseases can lead better lives.

Vertex scientists and our collaborators are working on new medicines to cure or significantly advance the treatment of hepatitis C, cystic fibrosis, epilepsy and other life-threatening diseases.

Founded more than 20 years ago in Cambridge, MA, we now have ongoing worldwide research programs and sites in the U.S., U.K. and Canada.

(VRTX-GEN)

Vertex Pharmaceuticals Incorporated

Investors:

Michael Partridge, 617-444-6108

or

Lora Pike, 617-444-6755

or

Matthew Osborne, 617-444-6057

or

Media:

Zachry Barber, 617-444-6470

Source: Vertex Pharmaceuticals Incorporated

News Provided by Acquire Media